Mission Statement

The Giri-Nathan Cardiovascular Health Services and Policy Research Lab focuses on using a variety of existing and novel data sources in combination with statistical modeling and econometric methodologies to address questions at the intersection of three major focus areas in health policy. These efforts are undertaken in collaboration with the Leonard Davis Institute of Health Economics, an interdisciplinary program with experts from the Wharton School of Economics and the Perelman School of Medicine.

Equitable Access to Cardiovascular Therapies

We seek to understand the geographic, racial, ethnic and socioeconomic factors associated with access to novel cardiovascular pharmacotherapies as well as therapeutic devices using novel datasets constructed from large administrative payor databases, geospatial databases and a variety of socioeconomic markers. 

• Nathan et al. JAMA Cardiology 2023.
• Nathan et al. JAMA Cardiology 2022.
• Nathan et al. Circ Cardiovasc Qual Outcomes 2021.

Factors Motivating the Adoption of Cardiovascular Therapies

We are interested in understanding financial and non-financial factors associated with the adoption of novel cardiovascular therapies by physician groups and health systems using economic and advanced statistical analyses of administrative and cost data sources.

• Reddy et al. Circulation Cardiovascular Interventions 2022.

Risk and Outcome Assessment when Utilizing Cardiovascular Therapies

We study the accuracy and utility of measuring patient-level outcomes following the use of cardiovascular therapies, as well as how these measurements can affect physician and health system decision making using administrative and registry data sources in combination with econometric and behavioral science methodologies.

• Nathan et al. Journal of the American College of Cardiology 2021.
• Yang and Nathan. et al. JAMA Cardiology 2021.
• Nathan et al. JAMA Cardiology 2020.

In collaboration with the Cardiovascular Outcomes and Quality Effectiveness Research Group (CAVOQER), our group uses large data sets, including administrative, registry and clinical trial data sources, in combination with advanced causal inference techniques to perform comparative effectiveness studies and outcome analyses of cardiovascular therapies in the following clinical areas.

Coronary Artery Disease

• Chatterjee and Giri et al.  JACC Cardiovascular Interventions 2021.
• Kobayashi and Giri et al. JAMA Cardiology 2017.
• Resor, Nathan and Mauri et al. Circulation 2016.

Structural Heart Disease

• Nathan et al. American Heart Journal 2021.
• Halaby and Nathan et al.  Circulation Cardiovascular Interventions 2021.
• Hyman and Giri et al. Circulation 2017.

Venous Thromboembolic Disease

• Giri et al. Circulation 2019.
• Adusumalli, Giri and Groeneveld et al Am Heart Journal 2019.
• Chatterjee and Giri et al. JAMA 2014

Reno-vascular Hypertension

• Kirtane and Kobayashi et al. JAMA Cardiology 2023.

Peripheral Arterial Disease

• Fanaroff, Nathan, Giri et al. JAHA 2021.
• Giri et al. JACC Cardiovascular Interventions 2015. 
• Giri et al. JACC Cardiovascular Interventions 2014.